Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: Changes seen and global implications

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 10, Issue 6, 2010, Pages 707-722

  Godman, Brian ^a,u,v   Shrank, William ^b   Andersen, Morten ^c   Berg, Christian ^d   Bishop, Iain ^e   Burkhardt, Thomas ^f   Garuoliene, Kristina ^g,w   Herholz, Harald ^h   Joppi, Roberta ^a,x   Kalaba, Marija ⁱ   Laius, Ott ^j   McGinn, Diane ^k   Samaluk, Vita ^l   Sermet, Catherine ^m   Schwabe, Ulrich ⁿ   Teixeira, Ins ^o   Tilson, Lesley ^p   Tulunay, F Cankat ^q   Vlahovi Palevski, Vera ^r   Wendykowska, Kamila ^s   Wettermark, Bjrn ^c,y   Zara, Corinne ^t   Gustafsson, Lars L ^c   more..

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^e HEALTHCARE IMPROVEMENT SCOTLAND   (United Kingdom)

^f Hauptverband der Osterreichischen Sozialversicherungstrager   (Austria)

^g VILNIUS UNIVERSITY   (Lithuania)

^h Kasemarzliche Vereinigung Hessen   (Germany)

ⁱ Republic Institute for Health Insurance   (Serbia)

^j State Agency of Medicines   (Estonia)

^k NHS North Lancashire   (United Kingdom)

^l Health Insurance Institute of Slovenia   (Slovenia)

^m IRDES   (France)

ⁿ UNIVERSITY OF HEIDELBERG   (Germany)

^o CEFAR   (Portugal)

^p National Centre for Pharmacoeconomics   (Ireland)

^q ANKARA UNIVERSITY   (Turkey)

^r KBC RIJEKA   (Croatia)

^s HTA CONSULTING   (Poland)

^t C Agy Hlth Technol Assess Res   (Spain)

^u UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^v KAROLINSKA INSTITUTE   (Sweden)

^w National Health Insurance Fund   (Lithuania)

^x Azienda Sanitaria Locale of Verona   (Italy)

^y STOCKHOLM COUNTY COUNCIL   (Sweden)

more..

Author keywords

cross national studies; demand side reforms; generic drugs; generic substitution; prescribing efficiency

Indexed keywords

ATORVASTATIN; ESOMEPRAZOLE; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; OMEPRAZOLE; PRAVASTATIN; PROTON PUMP INHIBITOR; ROSUVASTATIN; SIMVASTATIN;

AMBULATORY CARE; ARTICLE; AUSTRIA; DATA BASE; DOCUMENTATION; DRUG COST; DRUG UTILIZATION; EUROPE; FINANCE; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; METHODOLOGY; OBSERVATIONAL STUDY; PREDICTION; PRESCRIPTION; REIMBURSEMENT; RETROSPECTIVE STUDY; SCORING SYSTEM; WESTERN EUROPE;

AMBULATORY CARE; DATABASES, FACTUAL; DRUG COSTS; DRUGS, GENERIC; EUROPE; HEALTH CARE REFORM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMP INHIBITORS; QUALITY ASSURANCE, HEALTH CARE; RETROSPECTIVE STUDIES;

EID: 78650443213     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.10.72     Document Type: Article

References (83)

1. Simoens S. The Portuguese generic medicines market: a policy analysis. Pharm. Pract. 7, 74-80 (2009).
2. Sermet C, Andrieu V, Godman B et al. Ongoing pharmaceutical reforms in France; considerations for other countries and implications for key stakeholder groups in France. Appl. Health Econ. Health Policy 8, 7-24 (2010).
3. Wettermark B, Godman B, Andersson K et al. Recent national and regional drug reforms in Sweden - implications for pharmaceutical companies in Europe. Pharmacoeconomics 26, 537-550 (2008).
4. Godman B, Bucsics A, Burkhardt T et al. Insight into recent reforms and initiatives in Austria; implications for key stakeholders. Expert Rev. Pharmacoecon. Outcomes Res. 8, 357-371 (2008).
5. Heikkila R, Mantyselka P, Hartikainen-Herranen K, Ahonen R. Customers' and physicians' opinions of experiences with generic substitution during the first year in Finland. Health Policy 82, 366-374 (2007).
6. Orzella L, Chini F, Rossi P, Borgia P. Physician and patient characteristics associated with prescriptions and cost of drugs in the Lazio region of Italy. Health Policy 95, 236-244 (2010).
7. Wettermark B, Persson ME, Wilking N et al. Forecasting drug utilization and expenditure in a metropolitan health region. BMC Health Serv. Res. 10, 128 (2010).
8. Garattini L, Motterlini N, Cornago D. Prices and distribution margins of in-patent drugs in pharmacy: a comparison in seven European countries. Health Policy 85, 305-313 (2008).
9. Godman B, Wettermark B, Hoffman M et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden; global relevance. Expert Rev. Pharmacoecon. Outcomes Res. 9, 65-83 (2009).
10. Comma A, Zara C, Godman B et al. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction. Expert Rev. Pharmacoecon. Outcomes Res. 9, 569-581 (2009).
11. Barry M, Molloy D, Usher C, Tilson L. Drug expenditure in Ireland. Ir. Med. J. 101, 299-302 (2008).
12. Barry M, Usher C, Tilson L. Public drug expenditure in the Republic of Ireland. Expert Rev. Pharmacoecon. Outcomes Res. 10, 239-245 (2010).
13. Godman B, Shrank W, Wettermark B et al. Use of generics - a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3, 2470-2494 (2010).
14. Simoens S. Generic medicine pricing in Europe: current issues and future perspective. J. Med. Econ. 11, 171-175 (2008).
15. Seeley E, Kanavos P. Generic medicines from a societal perspective: savings for health care systems. Eurohealth 14, 18-22 (2008).
16. Seeley E. Maximizing the benefits from generic competition. Euro Observer 10, 8-11 (2008).
17. Simoens S. Trends in generic prescribing and dispensing in Europe. Exp. Rev. Clin. Pharmacol. 1, 497-503 (2008).
18. Simoens S. International comparison of generic medicine prices. Curr. Med. Res. Opin. 23, 2647-2654 (2007).
19. Perry G. The European generic pharmaceutical market in review: 2006 and beyond. J. Gen. Med. 4, 4-14 (2006).
20. McGinn D, Godman B, Lonsdale J et al. Initiatives to enhance the efficiency of statin and proton pump inhibitor prescribing in the UK; impact and implications. Expert Rev. Pharmacoecon. Outcomes Res. 10, 73-85 (2010).
21. Duerden M, Hughes D. Generic and therapeutic substitutions in the UK: are they a good thing? Br. J. Clin. Pharmacol. 70, 335-341 (2010).
22. Anon. Price falls are following a familiar pattern. Generics Bulletin 132, 23 (2010).
23. Allenet B, Barry H. Opinion and behaviour of pharmacists towards the substitution of branded drugs by generic drugs: survey of 1,000 community pharmacists. Pharm. WorldSci. 25, 197-202 (2003).
24. Godman B, Haycox A, Schwabe U et al. Having your cake and eating it: Office of Fair Trading proposal for funding new drugs to benefit patients and innovative companies. Pharmacoeconomics 26, 91-98 (2008).
25. Walley T. Drugs, money and society. Br. J. Clin. Pharmacol. 70, 342-345 (2010).
26. Wettermark B, Godman B, Jacobsson B, Haaijer-Ruskamp F. Soft regulations in pharmaceutical policymaking - an overview of current approaches and their consequences. Appl. Health Econ. Health Policy 7, 1-11 (2009).
27. Toth F. Healthcare policies over the last 20 years: reforms and counter-reforms. Health Policy 95, 82-89 (2010).
28. Brun M, Nobilio L, Ugolini C. Economic incentives in general practice: the impact of pay-for-particupation and pay-for-compliance programs for diabetes care. Health Policy 90, 140-148 (2009).
29. Mason A. New medicines in primary care: a review of influences on general practice prescribing. J. Clin. Pharm. Ther. 33, 1-10 (2008).
30. Sturm H, Austvoll-Dahlgren A, Aaserud M et al. Pharmaceutical policies: effects of financial incentives for prescribers. Cochrane Database Syst. Rev. (3), CD006731 (2007).
31. Martens M, Werkhoven M, Severens J, Winkens R. Effects of behaviour independent financial incentive on prescribing behaviour of general practitioners. J. Eval. Clin. Pract. 13, 369-373 (2007).
32. Mason A, Drummond D, Hunter J et al. Prescribing incentive schemes - a useful approach? Appl. Health Econ. Health Policy 4, 111-117 (2005).
33. Butzlaff M, Kempkens D, Schnee M et al. German ambulatory care physicians' perspective on clinical guidelines - a national survey. BMC Fam. Pract. 7, 47 (2006).
34. Prosser H, Almond S, Walley T. Influences on GPs' decision to prescribe new drugs - the importance of who says what. Fam. Pract. 20, 61-68 (2003).
35. Denig P, Witterman C, Schouten H. Scope and nature of prescribing decisions made by general practioners. Qual. Saf. Health Care 11, 137-143 (2002).
36. Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients' care. Lancet 362, 1225-1230 (2003).
37. Prosser H, Walley T. A qualitative study of GPs' and PCO stakeholders' views on the importance and influence of cost on prescribing. Soc. Sci. Med. 60, 1335-1346 (2005).
38. Pegler C, Underhill J. Evaluating promotional material from industry: an evidence-based approach. Pharmaceutical J. 274, 271-274 (2005).
39. Ferner R, Lenney W, Marriott J. Controversy over generic substitution. Br. Med. J. 340, c2548 (2010).
40. Valles J-A, Barreiro M, Cereza G et al. A prospective multicentre study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy 65, 269-275 (2003).
41. Shrank W, Cox E, Fischer M, Mehta J, Choudry N. Patients' perception of generic medications. Health Affairs 28, 546-556 (2009).
42. Kjoenniksen I, Lindbaek M, Grannas A. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm. WorldSci. 28, 284-289 (2006).
43. Sagardui-Villamor JK, Lacalle Rodriquez-Labajo M, Casado-Buendia S. [Substitution of generic for brand medicines in primary care. Factors associated to effuse change]. Aten Primaria 36, 498-493 (2005)
44. Andersson K, Jorgensem T, Carlsten A. Physicians' opinions and experiences of the pharmaceutical benefits reform. Scand. J. Public Health 34, 654-659 (2006).
45. Garattini S, Bertele V, Godman B et al. Enhancing the rational use of new medicines across European healthcare systems - a position paper. Eur. J. Clin. Pharmacol. 64, 1137-1138 (2008).
46. Walker A, Booth C, Brown A, Paterson K. How much good do new medicines do? Basic Clin. Pharm. Toxicol. 105(Suppl. 1), 29 (2009).
47. Wettermark B, Godman B, Eriksson C et al. [Introduction of new medicines into European healthcare systems]. GGW 10(3), 24-34 (2010).
48. Luijn J, Gribnau F, Leufkens H. Superior efficacy of new medicines? Eur. J. Clin. Pharmacol. 66, 445-448 (2010).
49. Lee T, Emanuel E. Tier 4 drugs and the fraying of the social compact. N. Engl. J. Med. 359, 333-335 (2008).
50. Ostoni R, Hegney D, Jackson C et al. Systematic review of interventions to improve prescribing. Ann. Pharmacother. 43, 502-513 (2009).
51. Grimshaw J, Thomas R, MacLennan G et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol. Assess. 8(6), iii-iv, 1-72 (2004).
52. Grimshaw J, Campbell M, Eccles M et al. Experimental and quasi-experimental designs for evaluating guidelines implementation strategies. Fam. Pract. 17, S11-S16 (2000).
53. Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics 27, 1-4 (2009).
54. Lindgren P, Graff J, Olson A et al. Cost-effectiveness of high-dose atorvastatin compared with regular simvastatin. Eur. Heart J. 28, 1448-1453 (2007).
55. Studies in Drug Utilization - Methods and Applications. Bergman U, Gimsson A, Wahba A, Westerholm B (Eds). WHO Regional Publications, Copenhagen, Denmark (1979).
56. World Health Organization (WHO). The selection of essential drugs. World Health Organ. Tech. Rep. Ser. No. 615 (1977).
57. R0nning M, Blix HS, Harb0 BT, Str0m H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose - are drug utilisation data comparable? Eur. J. Clin. Pharmacol. 56, 723-727 (2000).
58. Godman B, Burkhardt T, Bucsics A et al. Impact of recent reforms in Austria on utilisation and expenditure of PPIs and lipid lowering drugs; implications for the future. Expert Rev. Pharmacoecon. Outcomes Res. 9, 475-484 (2009).
59. Walley T, Folino-Gallo P, Schwabe U, Van Ganse E. Variations and increase in use of statins across Europe: data from administrative databases. Br. Med. J. 328, 385-386 (2004).
60. Vlahovic-Palcevski V, Gantumur M, Radosevic N et al. Coping with changes in the defined daily dose in a longitudinal drug consumption database. Pharm. World Sci. 32, 125-129 (2010).
61. Wettermark B, Pehrsson A, Juhasz-Haverinen M et al. Financial incentives linked to self-assessment of prescribing patterns - a new approach for quality improvement of drug prescribing in primary care. Qual. Prim. Care 17, 179-189 (2009).
62. Wettermark B, Godman B, Neovius M et al. Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment. Health Policy 94, 221-229 (2010).
63. Bero L, Grilli R, Grimshaw J et al. Getting research into practice. Br. Med. J. 317, 465-468 (1998).
64. Barton S. Using clinical evidence. Br. Med. J. 322, 503-504 (2001).
65. Walley T, Folin-Galo P, Stephens P, Van Ganse E. Trends in prescribing and utilisation of statins and other lipid lowering drugs across Europe 1997-2003. Br. J. Clin. Pharmacol. 60, 543-551 (2005).
66. Collins R, Armitage J, Parish S et al. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005-2016 (2003).
67. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology and the European Association for the Study of Diabetes. Eur. Heart J. 28, 88-136 (2007).
68. Josan K, Majumdar S, McAlister F. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ 178, 576-584 (2008).
69. Walley T, Folino-Gallo P, Schwabe U, Van Ganse E, Stephens P. Comparison of national administrative and commercial databases to monitor expenditure and costs of statins across Europe. Eur. J. Clin. Pharmacol. 60, 503-511 (2004)
70. Teixeira I, Vieira I. Pharmaceutical pricing and reimbursement information Portugal October 2008 http://ppri.oebig.at/Downloads/Results/ Portugal-PPRI-2008.pdf (Accessed 2 March 2010)
71. Beishon J, McBride T, Scharaschkin A. Prescribing costs in primary care. National Audit Office 2007 www.nao.org.uk/publications/0607/ prescribing-costs-in-primary-c. aspx?alreadysearchfor=yes (Accessed 20 June 2010)
72. European Commission. Communication from the Commission - executive summary of the Pharmaceutical Sector Inquiry Report. Reference EU Commission report. 8 July 2009 http://ec.europa.eu/competition/sectors/pharmaceuticals/ inquiry/communication-en.pdf(Accessed 30 May 2010)
73. OECD Health Data 2010 www.oecd.org/document/16/0,3343, en-2649-34631-2085200-1-1-1-1,00. html (Accessed 28 June 2010)
74. World Health Organisation (WHO) guidelines for ATC classification and DDD assignment 2009. Oslo, Norway Collaborating Centre for Drug Statistics Methodology www.whocc.no (Accessed 15 January 2010)
75. Office of Fair Trading (UK). The Pharmaceutical price regulation system - an OFT study. February 2007 www.oft.gov.uk/shared-oft/reports/ comp-policy/oft885.pdf (Accessed 20 June 2010)
76. Wessling A, Lundin D. The review of drugs against disease caused by acid stomach - a summary. Solna: Pharmaceuticals Benefits Board, 2006 www.tlv.se/Upload/Genomgangen/ summary-stomach-acid.pdf (Accessed 5 March 2010)
77. Eriksson G, Lundin D. The review of medicines for lipid disorders. 2009 www.tlv.se/Upload/Genomgangen/ summary-lipids.pdf(Accessed 20 June 2010) MeReC Extra. Nice appraises statins 2006 www.npc.co.uk/ebt/merec/cardio/cdlipids/ resources/merec-extra-no21.pdf(Accessed 20 June 2010)
78. MeReC Extra. Nice appraises statins 2006 http://www.npc.co.uk/ebt/merec/ cardio/ cdlipids/resources/merec-extra-no21.pdf
79. National Institute for Health and Clinical Excellence. Statins for the prevention of cardiovascular events. Technology appraisal 94 and related costing template and report. January 2006 www.nice.org.uk/(Accessed 20 June 2010)
80. AFSSAPS. Prise en charge therapeutic du patient dyslipidemique. March 2005 www.afssaps.fr/var/afssaps-site/storage/ original/application/ da2c055ce7845afe44d7aaca7c3f4de8.pdf (Accessed 20 June 2010)
81. WHO. Introduction to drug utilisation research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services www.who.int/medicines/areas/quality- safety/ safety-efficacy/Dr ug%2 0 utilization%20research.pdf (Accessed 30 January 2010)
82. Lewis J. 'NHS doesn't care about cost of medicine': drugs firms accused of profiteering by raising prices by one thousand percent (2010) www.dailymail.co.uk/news/article-1295610/ NHS-doesnt-care-cost-medicine-Drugs- firms-accused-profiteering-raising-prices-ONE-THOUSAND-cent.html (Accessed 20 July 2010)
83. Expert Reviews. Supplementary Tables www.expert-reviews.com/toc/erp/10/6